secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001104659-25-012921
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA exits DNA tagging business, cuts 20% headcount; Q1 revenue $1.2M (+34% YoY), net loss $2.7M
--------------------------------------------------------------------------------

- Revenue $1.2M (+34% YoY); operating loss $3.0M vs $3.8M; net loss $2.7M vs $1.1M.
- Exiting DNA Tagging segment; workforce reduction 20% (13% annual payroll cut); ~$300k severance in Q2 FY25.
- GMP Site 1 completed Jan 31, 2025, ISO 7/5 certified; projected annual revenue $10M-$30M at full capacity.
- Cash $9.3M as of Dec 31, 2024, includes $5.7M net from October registered direct offering.
- First-in-human clinical validation of Linea DNA in CAR-T therapy under Czech regulatory approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/0001104659-25-012921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/tm256524d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-012921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer